Examination of the usefulness of kangen-karyu in the metabolic syndrome patient

Examination of the usefulness of kangen-karyu in the metabolic syndrome patient - Examination of the usefulness of kangen-karyu in the metabolic syndrome patient

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032765

Enrollment

Registered

2018-07-01

Start date

2018-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metabolic syndrome

Interventions

the patient takes kangen-karyu 2.5g three times a day for six months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient who corresponds to diagnostic criteria of the metabolic syndrome.In addition, the patient whom it was judged an interview list to be a state of kitai, oketu

Exclusion criteria

Exclusion criteria: The patient who judged that a doctor was inappropriate

Design outcomes

Primary

Measure	Time frame
We evaluate home blood pressure, degree of obesity , total cholesterol, LDL cholesterol, HDL cholesterol, triglyceride , HbA1C, after taking kangen-karyu for six months	—

Secondary

Measure	Time frame
We evaluate subjective symptoms "kitai", "oketu" after taking kangen-karyu for six months	—

Countries

Japan

Contacts

Public ContactTsutomu Kitazawa

shinseikai toyama hospital internal medicine

kitazawa@shinseikai.or.jp0766522156

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026